Mike Mahoney

When Mahoney took charge, Boston Scientific was a troubled company — weighed down by the failed Guidant acquisition, product quality issues, legal liabilities, and a demoralized organization. Over the next decade, he transformed BSX into a consistent high-single-digit organic growth company with expanding margins and a reinvigorated product pipeline. Boston Scientific's product portfolio spans interventional cardiology (drug-eluting stents, structural heart), cardiac rhythm management (pacemakers, defibrillators), electrophysiology (heart rhythm disorder treatment), endoscopy, urology, and neuromodulation (spinal cord stimulation, deep brain stimulation). Mahoney's strategy focused on operational execution, product innovation, and strategic M&A to enter high-growth adjacencies. His key decisions involve product innovation pipeline (particularly in electrophysiology with pulsed field ablation technology), strategic acquisitions to enter new markets, geographic expansion in emerging markets, and managing the competitive dynamics against Medtronic, Abbott, and Edwards Lifesciences.